Compare CXW & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXW | ADMA |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2001 | 2012 |
| Metric | CXW | ADMA |
|---|---|---|
| Price | $20.45 | $10.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $32.00 | $25.67 |
| AVG Volume (30 Days) | 689.1K | ★ 4.9M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.19 | N/A |
| EPS | ★ 1.08 | 0.60 |
| Revenue | ★ $2,211,182,000.00 | $42,219,783.00 |
| Revenue This Year | $17.13 | $27.46 |
| Revenue Next Year | $5.64 | $22.11 |
| P/E Ratio | $18.97 | ★ $18.18 |
| Revenue Growth | 12.72 | ★ 43.85 |
| 52 Week Low | $15.74 | $7.21 |
| 52 Week High | $23.54 | $24.17 |
| Indicator | CXW | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 57.07 | 44.68 |
| Support Level | $19.27 | $7.21 |
| Resistance Level | $21.01 | $16.48 |
| Average True Range (ATR) | 0.52 | 0.47 |
| MACD | -0.03 | 0.29 |
| Stochastic Oscillator | 70.24 | 68.43 |
CoreCivic Inc is an owner and operator of private prisons and detention centers in the United States. It operates in three segments: Safety, Community, and Properties. The Community segment owns and operates residential reentry centers. The Properties segment owns properties for lease to third parties and government agencies. The vast majority of the company's revenue comes from the CoreCivic Safety segment which consists of correctional and detention facilities that are owned, or controlled via a long-term lease, and managed by the company, as well as those correctional and detention facilities owned by third parties but managed by CoreCivic.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.